OCTO Acquires Nebula Systems, Reinforces Its Leadership in Intelligent Vehicle Diagnostics
4.12.2019 14:00:00 EET | Business Wire | Press release
OCTO Telematics, the leading global provider in transforming an IoT Big Data set into actionable intelligence, has acquired the entire share capital of Nebula Systems Ltd.
Nebula specialises in the development of advanced cloud technologies for the automotive and connected car industries. This means that its proprietary technologies are now available to make vehicle systems and data more accessible, so that a vehicle’s health, status and operation can be monitored, analysed, diagnosed and maintained, faster and more effectively than ever before - anytime and anywhere.
OCTO continues its investment strategy in companies with high technological value, pursuing continuous portfolio innovation and market leadership. The acquisition confirms OCTO’s unwavering commitment to respond to the increasing demand for vehicle usage data analysis tools, with advantages for insurance, automotive and mobility companies with its increasingly integrated and complete offering.
Modern cars are full of sensors that generate huge amounts of valuable data that can be used to enhance both the driver and fleet manager experience. The vast majority of this data is related to OEM Electronic Control Unit (ECU), protocol and CAN bus which are difficult for the aftermarket to access. The Nebula Systems diagnostic cloud solution is based on an integrated circuit and a suite of vehicle data analysis software applications in order to better respond to the increased complexity. An integrated circuit, developed with proprietary technology, grants deep access to OEM level data. Vehicle telematics can therefore benefit from combining this telematics chipset with proprietary analysis software, which gives OCTO the ultimate flexibility and ease of access to OEM vehicle data by using a unique VIN-specific configuration file that contains the instructions to read Parameter ID (PID) sets from any OEM ECU on virtually any car.
This technology uniquely combines the proprietary chipset and a cloud-based VIN interpreter and configuration files builder to fully access all the ECUs and thousands of PIDs a vehicle may have.
“We are very proud of this latest acquisition which places OCTO amongst the leading providers of fleet telematics leasing and renting organizations” says Nicola Veratelli, OCTO Group CEO. “Amongst many trends that are changing the mobility sector there are some that have a significant impact on fleet managers, such as the need to integrate data coming from the vehicle, each different from the other and defined for each manufacturer. OCTO solves the complexity of interpreting this data and offers impactful solutions which contribute to deliver additional value for fleet managers. We are committed to offer dozens of fleet telematics services to fleet managers and drivers: remote cloud-based diagnostics deriving from this Nebula acquisition is surely one of the most relevant.”
With this acquisition, the Nebula technology will be integrated in the standard OCTO offering. Furthermore, all OCTO telematics devices will integrate these capabilities, allowing OCTO solutions full access to all OEM ECUs and to use diagnostic trouble codes and Parameter IDs for the benefit of both drivers and fleet managers. The combination of these benefits will have a substantial impact on mobility management costs for fleet managers using the OCTO Fleet Telematics solution.
About OCTO
Founded in 2002, OCTO is today the Number 1 global provider of telematics and data analytics solutions for the auto insurance industry and, increasingly, a major player in Fleet management services, with world-class solutions to grow its core businesses – Insurtech and Intelligent Mobility – and to expand and provide innovative connected solutions in new industries and international markets.
OCTO’s vision is to connect the world of mobility through advanced analytics and IoT-driven services for a new era of Smart Telematics.
OCTO currently has 6 million connected users, holds the largest global database of telematics data, with more than 248 billion miles of driving data collected and over 464,000 crashes and insurance events analysed, and runs more than 10 car sharing services with more than 400,000 hires per month.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005088/en/
Contact information
OCTO Telematics
Adriana Zambon
press.it@octotelematics.com
m: +39 339.3995640
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
